carbon monoxide has been researched along with Heritable Pulmonary Arterial Hypertension in 6 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patent foramen ovale is seen in a quarter of patients with idiopathic pulmonary arterial hypertension and associated with increased prevalence of severe hypoxemia but had no effect on long term survival." | 1.43 | Patent foramen ovale in idiopathic pulmonary arterial hypertension: Long-term risk and morbidity. ( Gallo de Moraes, A; Moua, T; Vakil, A, 2016) |
| "A subgroup of patients with idiopathic pulmonary arterial hypertension (IPAH) has severely reduced diffusing capacity of the lung for carbon monoxide (DLCO) and poor prognosis." | 1.39 | Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. ( Bogaard, HJ; Boonstra, A; de Man, FS; Groepenhoff, H; Grünberg, K; Leter, EM; Nossent, EJ; Trip, P; van den Berk, IA; Vonk-Noordegraaf, A; Westerhof, N, 2013) |
| "Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis." | 1.37 | Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. ( Allanore, Y; Berezne, A; Bletry, O; Clerson, P; Cottin, V; Couderc, LJ; Hachulla, E; Hatron, PY; Humbert, M; Launay, D; Le Pavec, J; Mouthon, L; Yaici, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sugiyama, Y | 1 |
| Matsubara, H | 1 |
| Shimokawahara, H | 1 |
| Ogawa, A | 1 |
| Hoeper, MM | 1 |
| Dwivedi, K | 1 |
| Pausch, C | 1 |
| Lewis, RA | 1 |
| Olsson, KM | 1 |
| Huscher, D | 1 |
| Pittrow, D | 1 |
| Grünig, E | 1 |
| Staehler, G | 1 |
| Vizza, CD | 1 |
| Gall, H | 1 |
| Distler, O | 1 |
| Opitz, C | 1 |
| Gibbs, JSR | 1 |
| Delcroix, M | 1 |
| Park, DH | 1 |
| Ghofrani, HA | 1 |
| Ewert, R | 1 |
| Kaemmerer, H | 1 |
| Kabitz, HJ | 1 |
| Skowasch, D | 1 |
| Behr, J | 1 |
| Milger, K | 1 |
| Lange, TJ | 1 |
| Wilkens, H | 1 |
| Seyfarth, HJ | 1 |
| Held, M | 1 |
| Dumitrescu, D | 1 |
| Tsangaris, I | 1 |
| Vonk-Noordegraaf, A | 2 |
| Ulrich, S | 1 |
| Klose, H | 1 |
| Claussen, M | 1 |
| Eisenmann, S | 1 |
| Schmidt, KH | 1 |
| Swift, AJ | 1 |
| Thompson, AAR | 1 |
| Elliot, CA | 1 |
| Rosenkranz, S | 1 |
| Condliffe, R | 1 |
| Kiely, DG | 1 |
| Halank, M | 1 |
| Trip, P | 1 |
| Nossent, EJ | 1 |
| de Man, FS | 1 |
| van den Berk, IA | 1 |
| Boonstra, A | 1 |
| Groepenhoff, H | 1 |
| Leter, EM | 1 |
| Westerhof, N | 1 |
| Grünberg, K | 1 |
| Bogaard, HJ | 1 |
| Szturmowicz, M | 1 |
| Kacprzak, A | 1 |
| Franczuk, M | 1 |
| Burakowska, B | 1 |
| Kurzyna, M | 1 |
| Fijałkowska, A | 1 |
| Skoczylas, A | 1 |
| Wesołowski, S | 1 |
| Kuś, J | 1 |
| Torbicki, A | 1 |
| Gallo de Moraes, A | 1 |
| Vakil, A | 1 |
| Moua, T | 1 |
| Launay, D | 1 |
| Humbert, M | 1 |
| Berezne, A | 1 |
| Cottin, V | 1 |
| Allanore, Y | 1 |
| Couderc, LJ | 1 |
| Bletry, O | 1 |
| Yaici, A | 1 |
| Hatron, PY | 1 |
| Mouthon, L | 1 |
| Le Pavec, J | 1 |
| Clerson, P | 1 |
| Hachulla, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension[NCT01347216] | 12,000 participants (Anticipated) | Observational | 2007-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for carbon monoxide and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension.
Topics: Arterial Pressure; Carbon Monoxide; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; H | 2022 |
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Topics: Carbon Monoxide; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; M | 2022 |
Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses.
Topics: Adult; Aged; Carbon Monoxide; Coronary Artery Disease; Familial Primary Pulmonary Hypertension; Fema | 2013 |
Low DLCO in idiopathic pulmonary arterial hypertension - clinical correlates and prognostic significance.
Topics: Adolescent; Adult; Age Factors; Aged; Carbon Monoxide; Coronary Artery Disease; Familial Primary Pul | 2016 |
Patent foramen ovale in idiopathic pulmonary arterial hypertension: Long-term risk and morbidity.
Topics: Adult; Aged; Carbon Monoxide; Cardiac Catheterization; Echocardiography; Familial Primary Pulmonary | 2016 |
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Topics: Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Carbon Monoxide; Comorbidity; Cross-Sectional | 2011 |